Your session is about to expire
← Back to Search
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Psoriasis (ARTISTYK Trial)
Phase 4
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1
≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at week 16
Awards & highlights
ARTISTYK Trial Summary
This trial studies how a drug can help improve quality of life for people with psoriasis.
Who is the study for?
This trial is for men and women who have had stable plaque psoriasis for at least 6 months, with moderate-to-severe symptoms. Participants should have a noticeable impact on their quality of life due to psoriasis and be suitable candidates for phototherapy or systemic therapy, with at least 3% body surface area affected.Check my eligibility
What is being tested?
The study is testing the effects of Deucravacitinib on improving the quality of life in people with plaque psoriasis compared to a placebo. It's set in a real-world community setting rather than a hospital.See study design
What are the potential side effects?
While specific side effects are not listed here, Deucravacitinib may cause typical drug-related adverse reactions which can include gastrointestinal issues, headaches, potential skin reactions, or other immune-mediated conditions.
ARTISTYK Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have moderate-to-severe plaque psoriasis.
Select...
At least 3% of my skin is affected by my condition.
ARTISTYK Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at week 16
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 16
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of participants who achieve Dermatology Life Quality Index (DLQI) score 0 or 1
Secondary outcome measures
Change from baseline in whole-body itch Numerical Rating Scale (NRS) score at week 16
Number of participants with a static Physician Global Assessment (s-PGA) score of 0 or 1 who had at least a 2-point reduction from baseline
Number of participants with adverse events (AEs)
+4 moreARTISTYK Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: DeucravacitinibExperimental Treatment1 Intervention
Group II: Placebo then DeucravacitinibPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~160
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,130,658 Total Patients Enrolled
36 Trials studying Psoriasis
19,906 Patients Enrolled for Psoriasis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My doctor thinks I should get light or drug treatment.I have had stable plaque psoriasis for over 6 months without major changes.I have moderate-to-severe plaque psoriasis.Your dermatology life quality index score is higher than 5 at the screening visit and day 1.At least 3% of my skin is affected by my condition.My psoriasis is not plaque type but another form like guttate or pustular.
Research Study Groups:
This trial has the following groups:- Group 1: Deucravacitinib
- Group 2: Placebo then Deucravacitinib
Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger